# Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)

> **NCT04075578** · — · UNKNOWN · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 60 (estimated)

## Conditions studied

- Bladder, Overactive

## Interventions

- **DRUG:** OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States

## Key facts

- **NCT ID:** NCT04075578
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-26
- **Primary completion:** 2020-05
- **Final completion:** 2020-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04075578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04075578, "Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04075578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*